Are cannabinoids effective for orofacial pain states?

B. Sessle

DOI: https://doi.org/10.11607/OFPH.2015.1.E

Abstract:A cute orofacial pains can generally be managed quite effectively by available therapeutic approaches, but most chronic orofacial pain conditions, especially those that are of a neuropath-ic nature, are still difficult to diagnose and treat. This is due in large part to the incomplete understanding of their underlying mechanisms and the limited efficacy or undesirable side effects of the drugs most frequently prescribed to relieve the pain. However, there is increasing attention being given in the media as well as in the biomedical sciences to the use as analgesic agents of the crude extracts of plants of the genus Cannabis (eg, marijuana) and their active ingredient delta 9-tetrahydrocannabinol (Δ9-THC). These cannabinoid compounds have been reported in the biomedical literature to be beneficial in the treatment of some types of neuropathic pain and other pain states. However, since some of the reports have significant experimental design limitations, the literature on this topic has been somewhat confusing and not always conclusive, and this has added to the current controversies around the legalization and use of cannabinoids for pain relief. Furthermore, the major focus of the research on cannabinoids as analgesic agents has been on their applicability for pain states outside the orofacial region. Therefore, the evidence base is quite limited for using cannabinoids for oro-facial pain conditions. A systematic review appearing in this issue of the Journal of Oral & Facial Pain and Headache (see Boychuk et al, pages 7–14) has assessed random-ized placebo-controlled trials (RCTs) of cannabinoids used in different populations of chronic nonmalig-nant neuropathic pain patients. This review has found evidence indicating that they may be effective analgesic agents for neuropathic pain conditions refrac-tory to other therapeutic approaches. Nonetheless, the review concludes that there is a need for more high-quality studies to evaluate the impact of the duration of drug treatment as well as to assess drug delivery approaches, such as oromucosal spray systems which are showing some promising results. There is also a need for RCTs that address specifically orofacial pain conditions. The clinical findings pointing to the usefulness of the cannabinoids for pain relief are supported by a growing body of evidence from basic science investigations addressing the possible efficacy and mechanisms of action of the cannabinoids in animal models of acute or chronic pain. This research, which has largely been directed at animal models of pain conditions in parts of the body outside the orofacial region, has …